Catabasis Pharmaceuticals & Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edas...
November 02 2018 - 7:00AM
Business Wire
Webinar at 1:00pm ET on November 7
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, and Parent Project Muscular Dystrophy
(PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of
Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne Muscular
Dystrophy,” on Wednesday, November 7, 2018 at 1:00pm ET.
Speakers Include:Joanne Donovan, M.D., Ph.D., Chief
Medical Officer, Catabasis PharmaceuticalsPat Furlong, Founding
President and Chief Executive Officer, Parent Project Muscular
Dystrophy
Dr. Donovan will discuss the Phase 3 PolarisDMD clinical trial
studying edasalonexent in Duchenne muscular dystrophy (DMD), which
is enrolling boys ages 4 to 7 (up to 8th birthday) regardless of
mutation type who have not been on steroids for at least 6 months.
Topics will include discussion of the PolarisDMD clinical trial,
endpoints, inclusion and exclusion criteria, and information on
edasalonexent, including previous clinical results that showed
preserved muscle function in boys affected by Duchenne with
edasalonexent treatment compared to the off-treatment period as
well as significantly improved biomarkers.
The webinar can be accessed by visiting
http://bit.ly/2Puskwr.
About EdasalonexentEdasalonexent (CAT-1004) is an
investigational oral small molecule that is being developed as a
potential new standard of care for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits
NF-kB, which is a key link between loss of dystrophin and disease
progression. NF-kB has a fundamental role in skeletal and cardiac
muscle disease in DMD. Catabasis is currently enrolling the single
global Phase 3 PolarisDMD trial to evaluate the efficacy and safety
of edasalonexent for registration purposes. In the clinic, we
observed that edasalonexent preserved muscle function and
substantially slowed disease progression compared to rates of
change in a control period, and significantly improved biomarkers.
Edasalonexent continues to be dosed in an open-label extension of
the MoveDMD Phase 2 clinical trial. The FDA has granted orphan
drug, fast track, and rare pediatric disease designations and the
European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. The
global Phase 3 PolarisDMD trial is currently enrolling boys
affected by Duchenne. For more information on edasalonexent and our
Phase 3 trial, please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181102005024/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2024 to May 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From May 2023 to May 2024